Sanofi Invests in Singapore Vaccine Production Site

Sanofi will be investing $434 million over five years to design a vaccine production center in Singapore, which will feature manufacturing and digital technologies. In partnership with the Singapore Economic Development Board, the new carbon-neutral site will mainly supply the Asian region and complement existing manufacturing capacities in Europe and North America.

Currently, the project is entering the design phase, with construction expected to begin in Q3 of this year. The five-year project is expected to see the site fully operational in Q1 2026, assuming all qualifications and validations of the first manufactured vaccine have been completed.

The factory will allow for production of three to four vaccines at the same time, compared to one in current industrial sites. The site will also have the flexibility to leverage multiple vaccine manufacturing technology platforms based on different cell types.

The project—Sanofi executives say—is expected to create up to 200 local jobs and enhance Singapore’s position as a regional innovation hub for the healthcare industry.

“As a major healthcare player, it’s our responsibility to act and to meet the unprecedented growing demands for vaccines,” comments Thomas Triomphe, executive vice president and global head of Sanofi Pasteur. “By investing in a new production site in Singapore, Sanofi is aiming to strengthen production capacity to meet ever-growing global demands on vaccines, and answer more rapidly to future pandemics.”